FAST NEWS: Legend Biotech’s revenue soars, but fails to turnaround losses
The latest: Legend Biotech Corp. (LEGN.US) announced Tuesday its second quarter revenue jumped 513% year-on-year to $73.33 million, mainly due to higher revenue from the sale of Carvykti, a product in collaboration…
Recent Articles
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Trade tensions threaten to unravel Texhong turnaround story
2678.HK
- Smithfield piques IPO investor appetite with turnaround story, low valuation
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
Cango gets crypto jolt back to revenue growth, profitability
CANG.US
-
Overseas losses put wrinkle in H World’s welcome mat
1179.HK HTHT.US
